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 SUMMARY STATEMENT 
This research demonstrates that the MAPK/ERK pathway controls the balance between 
proliferation and differentiation of embryonic precursors and identifies a potential 
mechanism underlying the pathogenesis of papillary craniopharyngioma. 
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ABSTRACT 
Despite the importance of the RAS-RAF-MAPK pathway in normal physiology and disease 
of numerous organs, its role during pituitary development and tumourigenesis remains 
largely unknown. Here we show that the over-activation of the MAPK pathway, through 
conditional expression of the gain-of-function alleles BrafV600E and KrasG12D in the 
developing mouse pituitary, results in severe hyperplasia and abnormal morphogenesis of the 
gland by the end of gestation. Cell-lineage commitment and terminal differentiation are 
disrupted, leading to a significant reduction in numbers of most of the hormone-producing 
cells before birth, with the exception of corticotrophs. Of note, Sox2+ve stem cells and 
clonogenic potential are drastically increased in the mutant pituitaries. Finally, we reveal that 
papillary craniopharyngioma (PCP), a benign human pituitary tumour harbouring BRAF 
p.V600E also contains Sox2+ve cells with sustained proliferative capacity and disrupted 
pituitary differentiation. Together, our data demonstrate a critical function of the MAPK 
pathway in controlling the balance between proliferation and differentiation of Sox2+ve cells 
and suggest that persistent proliferative capacity of Sox2+ve cells may underlie the 
pathogenesis of PCP.    
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INTRODUCTION 
In vertebrates, the pituitary gland is considered to be  master regulator of homeostasis 
because it regulates a wide range of essential physiological functions such as metabolism, 
growth, fertility and the stress response. The pituitary gland comprises anterior, intermediate 
and posterior lobes (AL, IL, and PL, respectively). The AL and IL derive from Rathke’s 
pouch, a dorsal evagination of the oral ectoderm at the boundary with the pharyngeal 
endoderm. The PL develops from a diverticulum at the ventral midline of the diencephalon, 
the infundibulum. At 18.5 dpc, the AL contains five hormone-expressing cell types: 
somatotrophs, lactotrophs, thyrotrophs, gonadotrophs and corticotrophs, which secrete 
growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), gonadotropins 
(FSH and LH) and adrenocorticotropin hormone (ACTH), respectively (Kelberman et al., 
2009). In addition, the AP contains Sox2+ve/Sox9+ve cells, a proportion of which represent 
stem cells in the postnatal pituitary (Castinetti et al., 2011; Andoniadou et al., 2013; Rizzoti 
et al., 2013). These cells are concentrated around the pituitary cleft in the IL and the 
“marginal zone”, a region of the dorsal AL mostly devoid of hormone-producing cells 
(Fauquier et al., 2008; Garcia-Lavendeira et al., 2009; Goldsmith et al., 2016; Perez-Millan et 
al., 2016). Dispersed Sox2+ve/Sox9+ve cells are also detected throughout the parenchyma of 
the AL, intermingled with hormone-expressing cells (Mollard et al., 2012). The IL contains 
melanotrophs, which express melanocyte-stimulating hormone (MSH). The PL is devoid of 
endocrine cell types and contains the axonal projections from hypothalamic neurons.  
Several signalling pathways and transcription factors regulate the normal 
development of the pituitary gland. Around 9.5 days post coitum (dpc), secreted signals from 
the prospective hypothalamus such as FGF8, FGF10, BMP4 and SHH are required for RP 
induction and for the expression of transcription factors including Hesx1, Sox2, Lhx3 and 
Lhx4 in RP progenitors (Ericson et al., 1998; Treier et al., 1998; Treier et al., 2001). RP 
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progenitors divide actively from 9.5 to 14.5 dpc (Davis et al., 2011) to generate post-mitotic 
precursors that initiate cell-lineage commitment by expressing: (i) Sf1 (Nr5a1), in the 
gonadotroph cell lineage (Schimmer and White, 2010), (ii) The T-box transcription factor 
Tpit, responsible for the activation of the proopiomelanocortin (Pomc1) gene in corticotrophs 
(and melanotrophs of the intermediate lobe) (Lamolet et al., 2001) and (iii) POU Class 1 
homeobox 1 (Pou1f1 or Pit1), which control the differentiation of thyrotrophs, lactotrophs 
and somatotrophs (Dolle et al., 1990). Mouse mutants and humans carrying inactivating 
mutations in most of these genes develop hypopituitarism (Fang et al., 2016). 
The mitogen-activated protein kinase (MAPK) pathway encompasses different 
signalling cascades, of which the Ras-Raf-Mek-ERK1/2 (hereafter MAPK/ERK) is one of the 
most dysregulated in human cancer and additionally, plays important roles during normal 
physiology (Dhillon et al., 2007) (Zhang and Liu, 2002). Extracellular growth factors (FGFs, 
EGF and PDGF among others) bind to and activate receptor tyrosine kinases, causing a 
downstream phosphorylation cascade (RAS-RAF-MEK-ERK), which eventually leads to 
transcription of target genes controlling cellular proliferation, differentiation, apoptosis and 
senescence. Gain-of-function mutations in components of the pathway, such as BRAF 
p.V600E and KRAS p.G12D, have been identified in numerous tumours and cancers (Dhillon 
et al., 2007). These mutations lead to the over-activation of the MAPK/ERK pathway and 
increase cell proliferation and survival, resulting in cell transformation and tumourigenesis. 
In pituitary tumours, biochemical evidence indicates that this pathway is activated in many 
types of pituitary adenoma in humans (Dworakowska et al., 2009). However, mutations in 
components of the pathway have been identified only in papillary craniopharyngioma (PCP); 
specifically the BRAF p.V600E mutation is present in the vast majority of the tumours 
analysed (Brastianos et al., 2014).  
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In this manuscript, we have addressed the role of MAPK/ERK pathway during normal 
pituitary development and in tumourigenesis by conditionally activating this pathway in RP 
progenitors during embryonic development. Our results demonstrate that persistent activation 
of the pathway leads to a drastic increase in the proliferative capacity of Sox2+ve cells and 
impairment of their differentiation properties resulting in enlargement of the Sox2+ve stem 
cell compartment by the end of gestation. Additionally, expression analysis of human tumour 
samples strongly suggests that similar mechanisms underlie the pathogenesis of PCP.  
 
RESULTS 
 
Severe anterior lobe hyperplasia and neonatal lethality in Hesx1
Cre/+
;Braf
V600E/+ 
and  
Hesx1
Cre/+
;Kras
G12D/+ 
mutants  
We have previously shown that the Hesx1-Cre mouse line drives robust Cre-mediated 
activity in the developing pituitary gland by 9.0 dpc (Andoniadou et al., 2007; Gaston-
Massuet et al., 2011; Jayakody et al., 2012). To assess the role of the MAPK/ERK pathway 
during development, we crossed the Hesx1
Cre/+
 mice with either Braf
V600E/+
or Kras
G12D/+ 
animals (Jackson et al., 2001; Dhomen et al., 2009). Genotypic analysis of 10.5-18.5 dpc 
embryos showed no statistically significant variation from the expected Mendelian ratios 
(Supplementary Table 1). In contrast, genotyping of postnatal mice from birth to 3 weeks 
failed to identify any viable Hesx1
Cre/+
;Braf
V600E/+ 
or  Hesx1
Cre/+
;Kras
G12D/+ 
mice 
(Supplementary Table 1). Histological examination revealed the presence of expanded 
airway structures in both mouse models at 18.5 dpc, suggesting that abnormal lung 
development could be the cause of the perinatal death observed (Supplementary Fig. 1) 
(Tang et al., 2011). 
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Haematoxylin-eosin staining of Hesx1
Cre/+
;Braf
V600E/+ 
and  Hesx1
Cre/+
;Kras
G12D/+ 
mutants at 10.5 dpc revealed no gross morphological defects in the developing RP of these 
mutants compared with control littermates (Fig. 1A-C). The first clear evidence of a 
morphological defect, typically anterior pituitary hyperplasia, was observed at 12.5 dpc and 
further pronounced by 14.5 dpc (Fig. 1D-I). At 18.5 dpc, a fully penetrant phenotype of 
severe anterior pituitary hyperplasia with branched cleft was observed in all embryos 
analysed (Fig. 1J-L). Cell counts of dissociated pituitaries at 18.5 dpc revealed a total of 
96000 ± 2.7% in the Hesx1
Cre/+
;Braf
V600E/+
mutant (p=<0.01), 101666 ± 4.3% in the 
Hesx1
Cre/+
;Kras
G12D/+
 mutant (p=<0.01) and 67200 ± 3.5% in control wild-type mice (Fig. 
1M). The posterior lobe was present and apparently normal in Hesx1
Cre/+
;Braf
V600E/+ 
and  
Hesx1
Cre/+
;Kras
G12D/+ 
mutant pituitaries (Fig. 1J-L). These data suggest that RP induction 
occurs normally in the Hesx1
Cre/+
;Braf
V600E/+
 and Hesx1
Cre/+
;Kras
G12D/+
  mutants, followed by 
an increase in proliferation, leading to hyperplasia of the anterior pituitary by the end of 
gestation.  
 
The MAPK/ERK pathway is regulated temporally and spatially during normal 
pituitary development 
The expression pattern of Braf and Kras mRNA and pERK1/2 protein expression, as a 
readout of activated MAPK/ERK pathway, were respectively analysed by in situ 
hybridisation and immunostaining, on histological sections of wild-type, 
Hesx1
Cre/+
;Braf
V600E/+ 
and  Hesx1
Cre/+
;Kras
G12D/+ 
embryos.  
At 10.5 dpc wild-type embryos, Braf and Kras mRNA were clearly detected in the 
prospective hypothalamus, including the posterior diencephalon and pre-optic area, in 
addition to the developing RP (Fig. 2A,D). At 12.5 and 14.5 dpc, transcripts were detected 
throughout the developing pituitary, including the infundibulum, periluminal epithelium and 
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anterior lobe (Figure 2B,E; data not shown). At 18.5 dpc, the expression domain of Kras 
and Braf was restricted to the periluminal area including the intermediate lobe and marginal 
zone with scattered cells dispersed throughout the anterior lobe (Fig. 2C,F). The expression 
patterns of Braf in Hesx1
Cre/+
;Braf
V600E/+
 (Fig. 3A-C) and Kras in Hesx1
Cre/+
;Kras
G12D/+ 
 
(data not shown) mutants were comparable to those in wild-type embryos.  
These expression patterns of mRNA expression did not correlate with pERK1/2 
detection at all embryonic stages. At 10.5 dpc, pERK1/2 expression was comparable between 
genotypes in both the developing hypothalamus and RP (Fig. 4A,E,I), corresponding with 
the Braf and Kras mRNA expression (Fig. 2). In contrast, at 12.5 and 14.5 dpc, very few 
pERK1/2+ve cells were detected, despite the broad expression of Braf and Kras mRNA in 
mutant and wild-type embryos (Fig. 4B,C,F,G,J,K) as well as the extensive expression of 
BRAF-V600E mutant protein throughout the Hesx1
Cre/+
;Braf
V600E/+
 pituitary (Fig. 3D-F). At 
18.5 dpc, the expression of pERK1/2 was noticeably increased in both Hesx1
Cre/+
;Braf
V600E/+ 
and  Hesx1
Cre/+
;Kras
G12D/+ 
mutants compared with the control pituitaries (Fig. 4D,H,L) and 
correlated with the in situ data (Fig. 2 and 3; data not shown). Together, these expression 
studies demonstrate that the MAPK/ERK pathway is temporally regulated with the highest 
levels observed at 10.5 and 18.5 dpc. In addition, we show that most of the cells up-
regulating the pathway are located in the epithelium lining the cleft, an area enriched for 
Sox2+ve undifferentiated embryonic precursors and stem cells (Andoniadou et al., 2013).  
 
Over-activation of the MAPK/ERK pathway results in abnormal terminal 
differentiation of specific hormone-producing cells  
To assess the effects of the over-activation of the MAPK/ERK pathway in Rathke’s pouch 
(RP) induction, cell lineage commitment and terminal differentiation, we performed detailed 
expression analyses at 10.5, 14.5 and 18.5 dpc in both mutants in comparison with controls. 
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The expression of Fgf10, Bmp4 and Shh within the hypothalamus is required for Lhx3 
activation in RP progenitors (Ericson et al., 1998; Treier et al., 1998; Treier et al., 2001). At 
10.5 dpc, the expression domains of these markers were indistinguishable between mutants 
and controls, supporting the notion that early RP induction occurs normally in the 
Hesx1
Cre/+
;Braf
V600E/+
 and Hesx1
Cre/+
;Kras
G12D/+
 mutant embryos (Supplementary Fig. 2). 
Immunostaining against POU1F1 (PIT1), NR5A1 (SF1) and TPIT, markers of specific cell-
lineage precursors of the anterior pituitary, revealed evident defects in the Hesx1
Cre/+
; 
Braf
V600E/+ 
mutants relative to control embryos at 14.5 dpc (Fig. 5A-I). Specifically, the 
proportion of PIT1+ve cells were significantly reduced relative to total cells (control, 29%, 
Braf mutant, 4%, p=0.001), SF1+ve cells were almost absent (control, 4%; Braf mutant, 
0.5%; p=<0.05) and TPIT+ve cells were increased (control, 10%; Braf mutant, 26%; 
p=0.001) (Fig. 5J). In the Hesx1
Cre/+
;Kras
G12D/+ 
mutants, PIT1+ve and SF1+ve cell lineage 
precursors were also significantly reduced (PIT1+ve: control, 29%; Kras  mutant, 13%; 
p=<0.01; SF1+ve: control, 4.5%; Kras mutant, 0.6%; p=<0.05), albeit to a lesser extent than 
in Hesx1
Cre/+
;Braf
V600E/+
mutants. Numbers of TPIT+ve cells were similar (control, 10%; Kras 
mutant, 12%; p=0.6156) (Fig. 5J). 
Total numbers of hormone-producing cells were calculated by adjusting the 
proportion of each of these cell types to the size of the pituitary gland of the 
Hesx1
Cre/+
;Braf
V600E/+
, Hesx1
Cre/+
;Kras
G12D/+
 and control embryos at 18.5 dpc (See Materials 
and Methods). We reasoned that this approach could avoid any bias in the quantitative 
analysis due to the hyperplasia observed in the mutant pituitaries; for instance, numbers of a 
particular cell type could be the same in mutant and controls but distributed in more 
histological sections in the mutant pituitary, hence seeming proportionally reduced. Overall, 
specific immunostaining revealed abnormal terminal differentiation of hormone-producing 
cells in both Hesx1
Cre/+
;Braf
V600E/+ 
and  Hesx1
Cre/+
;Kras
G12D/+ 
mutants, although the effects 
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were more accentuated in the former (Fig. 6A-R). Specifically, numbers of somatotrophs 
(GH+ve) (WT - 23560, Braf mutant - 3185), lactotrophs (PRL+ve) (WT - 17604, Braf mutant 
-  3233) and thyrotrophs (TSH+ve) (WT - 4043, Braf mutant - 664) (i.e. the Pit1 cell-lineage) 
were significantly reduced, and gonadotrophs (FSH+ve) (WT - 6134, Braf mutant - 1686) 
and LH+ve (WT - 1564, Braf mutant - 23) almost completely absent in Hesx1
Cre/+
;Braf
V600E/+ 
mutant pituitaries relative to controls (Fig. 6S). Immunostaining against GSU (WT - 6861, 
Braf mutant - 2977) confirmed the reduction of thyrotrophs and gonadotrophs in the mutant 
pituitaries (Supplementary Fig. 3). In contrast, total numbers of corticotrophs (ACTH+ (WT 
- 15958, Braf mutant - 28778) appeared significantly elevated in Hesx1
Cre/+
;Braf
V600E/+ 
mutants  (Fig. 6S). Abnormal differentiation was also observed in the Hesx1
Cre/+
;Kras
G12D/+ 
mutant pituitaries, but to a lesser extent, with a reduction in numbers of  thyrotrophs (WT - 
4043, Kras mutant -1371), gonadotrophs (FSH+ve (WT - 6134, Kras mutant - 4044) and 
lactotrophs (WT -17604, Kras mutant - 6710). Similar to Hesx1
Cre/+
;Braf
V600E/+ 
mutants, 
elevated numbers of corticotrophs were also observed in Hesx1
Cre/+
;Kras
G12D/+ 
mutant 
pituitaries (WT – 15958, Kras mutant - 21370) (Fig. 6S). Furthermore, absolute 
quantification of mRNA transcripts using quantitative RT-PCR from 18.5 dpc control, 
Hesx1
Cre/+
;Kras
G12D/+
and Hesx1
Cre/+
;Braf
V600E/+ 
pituitaries revealed a significant decrease in 
Gh and a trend towards increased Acth mRNA in both mutant genotypes (Fig. 6T), in 
agreement with the cell counts.  
Together, these analyses demonstrate that cell-lineage commitment and terminal 
differentiation are severely disrupted upon activation of the MAPK pathway in RP embryonic 
precursors, with an overall reduction of hormone-producing cells at the end of gestation.  
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 Increased proliferation of the developing pituitary in Hesx1
Cre/+
;Braf
V600E/+ 
and  
Hesx1
Cre/+
;Kras
G12D/+ 
embryos 
Analysis of cell proliferation of RP progenitors was carried out at 12.5, 14.5 and 18.5 dpc in 
Hesx1
Cre/+
;Braf
V600E/+
, Hesx1
Cre/+
;Kras
G12D/+ 
and control pituitaries. Quantitative analysis of 
the proliferation index using Ki67 staining, a marker of cycling cells, revealed no difference 
at 12.5 dpc, with around 70% of total cells being Ki67+ve (Fig. 7A-C, J). However, a 
significant increase in Ki67+ve cells at 14.5 and 18.5 dpc was observed in both mutant 
genotypes, relative to stage-matched controls (Fig. 7D-J). Of note, while the Ki67 
proliferation index decreased gradually in control pituitaries from 72% at 12.5 dpc to 22% at 
18.5 dpc, this progressive quiescence was not observed to the same degree in the 
Hesx1
Cre/+
;Kras
G12D/+
 or Hesx1
Cre/+
;Braf
V600E/+ 
mutants. At 18.5 dpc, the proportion of 
proliferating cells fell to only 42% in Hesx1
Cre/+
;Kras
G12D/+
 and 55% in Hesx1
Cre/+
;Braf
V600E/+ 
mutant pituitaries (Fig. 7J). Increased proliferation was also confirmed by immunostaining 
against Cyclin D2, which controls G1/S cell cycle progression and is mainly expressed in RP 
progenitors in the periluminal epithelium (Bilodeau et al., 2009). Quantification of Cyclin 
D2-expressing cells out of total DAPI-stained nuclei within the periluminal epithelium 
revealed an increased trend in both mutant genotypes at 12.5 dpc compared with stage-
matched controls (Supplementary Fig. 4). 
 
Activation of the MAPK/ERK pathway results in expansion of the Sox2 stem cell 
compartment  
The restricted expression of pERK1/2 and increased proliferation of periluminal cells, 
prompted us to assess whether the Sox2+ve cells could be the main population responding to 
the over-activation of the MAPK/ERK pathway in our mouse models. Histological sections 
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of Hesx1
Cre/+
;Braf
V600E/+
, Hesx1
Cre/+
;Kras
G12D/+ 
and control pituitaries were analysed by 
immunostaining at different developmental stages. At 12.5 dpc the proportion of Sox2+ve 
cells was initially similar between genotypes at around 80% of total cells (Fig. 8A-C, J). 
However, in control embryos numbers of Sox2+ve cells fell to 21% by 18.5 dpc (p=0.0004) 
(Fig. 8G, J). Strikingly, in Hesx1
Cre/+
;Kras
G12D/+
 and Hesx1
Cre/+
;Braf
V600E/+ 
mutant pituitaries 
the high proportion of Sox2+ve cells found at earlier developmental time points was 
maintained, falling to only 53% (p=0.0519) and 72% (p=0.068) of total cells at 18.5 dpc, 
respectively. This suggests a trend towards a decrease in Sox2+ve cell numbers although not 
statistically significant (Fig. 8H-J). Further to this, levels of Sox2 mRNA were observed to 
be significantly increased in Hesx1
Cre/+
;Braf
V600E/+
mutants by quantitative RT-PCR (Fig. 
8K). Corroborating the histological findings, the clonogenic potential in 
Hesx1
Cre/+
;Kras
G12D/+
 and Hesx1
Cre/+
;Braf
V600E/+ 
pituitaries at 18.5 dpc was nearly three and 
five times higher, respectively, than in controls when analysed in stem cell promoting 
medium (Fig. 8L,M). 
 The described defects suggest that the MAPK pathway may control the balance 
between self-renewal and differentiation of Sox2+ve progenitors during development. To 
further characterise this defect, we performed a pulse chase experiment with the nucleotide 
analogue EdU, which is incorporated during the S phase of the cell cycle. Specifically, we 
injected EdU at 14.5 dpc, when most of the replicating cells are Sox2+ve progenitors and 
analysed the pituitaries 48 hours later at 16.5 dpc, when progenitors have exited cell cycle to 
commit to specific cell lineages (Fauquier et al., 2008; Bilodeau et al., 2009). This was 
performed in both control and Hesx1
Cre/+
;Braf
V600E/+
embryos, due to their more pronounced 
phenotype.  
In control embryos, approximately 25% of the initially labelled EdU cells expressed 
the commitment marker PIT1 and around 21% expressed SOX2 (Fig. 9A, C, D,F). In 
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contrast, in Hesx1
Cre/+
;Braf
V600E/+ 
mutants, the percentage of EdU+/PIT1+ cells dropped to 
3% and the proportion of EdU+/Sox2+ cells was elevated to 40% (Fig. 9B,C,E,F). Despite 
the significant increase in ACTH+ve cells in the mutant pituitary at 18.5 dpc, the proportion 
of EdU+/TPIT+ positive in this tracing experiment remained similar between genotypes (8% 
in controls and 9% in mutants) (Fig. 9H-I). This tracking experiment also revealed a higher 
proportion of EdU+/Ki67+ cells in the Hesx1
Cre/+
;Braf
V600E/+ 
mutants (25%) relative to the 
controls (18%) (Fig. 9J-L).  To assess which cells were labelled at 14.5 dpc, we performed a 
short pulse experiment by injecting EdU in pregnant females at 14.5 dpc and analysed the 
embryos 2 hours later. This analysis confirmed the majority of the EdU+ cells expressed 
SOX2, specifically 74% of labelled EdU+ cells expressed SOX2 in the control and 87% in 
the Hesx1
Cre/+
;Braf
V600E/+ 
mutants pituitaries, suggesting a trend towards an increase although 
not significant (p=0.1599) (Supplementary Fig. 5A-C). In the control pituitary, 6% of the 
EDU+ cells expressed PIT1 and 1.4% TPIT, whilst in the mutant pituitary these proportions 
were 0.1% for PIT1 and 3.7% for TPIT, both significantly different (p=0.0246, PIT1 and 
p=0.0490, TPIT) (Supplementary Fig. 5D-I). Three conclusions can be drawn from these 
EdU studies: (i) the activation of the MAPK/ERK pathway drives self-renewal versus 
differentiation of Sox2+ve cells; (ii) there is a blockade in the differentiation of Sox2+ve 
cells into PIT1 progenitors; (iii) there is no bias in the differentiation of Sox2+ve cells into 
the TPIT cell lineage; rather TPIT progenitor respond to the pathway activation by increasing 
proliferation. Together, these data demonstrate that the activation of the MAPK pathway in 
embryonic precursors results in significant expansion of the Sox2+ve cell population and 
increased clonogenic potential. In addition, we show that an abnormal balance between self-
renewal and differentiation contribute to these defects.  
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Sox2+ve cells represent the major proliferating cell population in human papillary 
craniopharyngioma 
Higher numbers of organ-specific stem cells with reduced differentiation potential can lead to 
tumourigenesis in many organs including the pituitary gland (Gaston-Massuet et al., 2011). 
As BRAF p.V600E is the sole genetic event associated with human papillary 
craniopharyngioma (PCP), we hypothesised that over-activated MAPK in these tumours may 
lead to similar cellular alterations to those observed in the Hesx1
Cre/+
;Braf
V600E/+ 
mutant 
pituitary, i.e. expansion of the Sox2/Sox9+ve cells with decreased differentiation capacity.  
PCPs are histologically characterised by the presence of cores of fibrovascular stroma 
lined by basal cells and suprabasal layers of well-differentiated non-keratinised squamous 
epithelium (Fig. 10A). PCPs are non-functional tumours, which do not express pituitary 
hormones (Louis et al., 2016). In a series of archival FFPE PCP specimens (n=5), we 
confirmed the presence of p.BRAF(V600E) mutations (Supplementary Table 2)  and 
expression of BRAFV600E in all tumour cells (Fig. 10B; light brown staining). pERK1/2 
staining was more restricted and focused in areas around the fibrovascular cores (Fig. 10E).  
Most of the cells in the tumours were positive against a pan-cytokeratin antibody recognising 
cytokeratins, but cells from the basal layer were negative (Fig. 10C; dark brown staining). 
This was further evidenced by immunostaining against cytokeratin 19 (Fig. 10D; light brown 
staining). Double immunostaining revealed that the squamous epithelial tumour components 
robustly expressed SOX2 and SOX9 in a graded manner, with the highest expression 
observed in basal cells immediately in contact with the fibrovascular cores and a progressive 
loss of signal in cells away from the SOX2+/SOX9+ve areas (Fig. 10F-H). Quantification 
analyses demonstrated that approximately 16% of these Sox2+ve cells expressed Ki67 (Fig. 
10I-L). Moreover, up to 91% of all cycling cells within the tumour (excluding host-derived 
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stroma) co-expressed SOX2, suggesting that proliferating SOX2+ve cells may be driving 
PCP growth (Fig. 10L). 
For comparison purposes, we assessed the proliferative potential of Sox2+ve cells 
during normal human embryonic pituitary development and adulthood. At CS20 (Carnegie 
stage 20; gestational day 49), an embryonic stage that is analogous to 14.5 dpc in mouse, 
human fetal pituitaries were predominantly SOX2;SOX9+ve and almost the majority of these 
cells expressed Ki67 (Supplementary Fig. 6A-C,J-L). In contrast, adult human pituitary 
samples contained very few SOX2+ve cells in the anterior lobe (Supplementary Fig. 6D-I), 
which very rarely expressed Ki67 with an almost mutual exclusivity between these two 
markers (Supplementary Fig. 6M-R). These observations suggest that, as in the mouse 
model, the activation of the MAPK pathway in human PCP tumours result in increased 
proliferative capacity and reduced terminal differentiation of the Sox2+ve cells.  
 
DISCUSSION 
 
In this manuscript we show that the over-activation of the MAPK pathway in RP embryonic 
precursors results in increased, sustained proliferation and impaired terminal differentiation 
of Sox2+ve cells during development. Consequentially, by the end of gestation, the pituitary 
gland contains vast numbers of Sox2+ve cells leading to an enlargement of the pituitary stem 
cell compartment. Because the Hesx1-Cre mouse line drives Cre-mediated recombination in 
the anterior hypothalamus, we cannot completely rule out a hypothalamic contribution to the 
observed phenotype. However, the normal hypothalamic patterning at 10.5 dpc supports a 
more relevant role for the dysregulation of the MAPK/ERK pathway in the developing RP. 
Of translational relevance, we reveal the presence of a population of Sox2+ve cells in human 
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PCP tumours bestowed of proliferating capacity but unable to differentiate into hormone-
producing pituitary cells. 
Our data suggest that the activation of the MAPK/ERK pathway by FGF ligands is 
critical during pituitary development. The FGF family of secreted factors binds to tyrosine 
kinase FGF receptors (FGFRs) to signal through the MAPK/ERK and other pathways (Ornitz 
and Itoh, 2015). Several FGFs including Fgf8, 10 and 18 are expressed in the developing 
ventral diencephalon around 9.5-10.5 dpc (Treier et al., 1998; Treier et al., 2001) and loss-of-
function mutants of FGF and FGFR2, demonstrate that FGF signalling is required for normal 
proliferation of RP progenitors and pituitary morphogenesis (De Moerlooze et al., 2000; 
Ohuchi et al., 2000). Ex vivo culture of RP tissue exposed to FGFs and FGF inhibitors has 
revealed a critical function for the pathway in controlling both RP proliferation and, its down-
regulation is required for normal PIT1-cell lineage specification (Ericson et al., 1998; Norlin 
et al., 2000). Of note, transgenic ectopic expression of Fgf8 in the developing pituitary using 
a Cga (a-GSU) promoter results in pituitary hyperplasia and expansion of ACTH-expressing 
cells (corticotrophs and melanotrophs) with a concomitant severe loss of gonadotrophs, 
somatotrophs, thyrotrophs and gonadotrophs (Treier et al., 1998), a phenotype resembling our 
mouse models activating the MAPK-ERK pathway. The data presented here open the 
possibility that other ligands such as EGF, PDGF and TGF, which, like FGFs can activate 
the MAPK/ERK pathway, may be important during pituitary development. Alternatively, it is 
also possible that FGF is the only secreted signal activating the MAPK/ERK pathway in RP. 
Further analyses are required to clarify the contributions of other signals besides FGFs. 
We reveal a critical function of the MAPK/ERK pathway in the control of the stem 
cell compartment in the pituitary by the end of gestation. The proportion of Sox2+ve cells is 
drastically increased and comprises almost ¾ of the entire cell population in the 
Hesx1
Cre/+
;Braf
V600E/+
 at 18.5 dpc. Our analyses show that this substantial expansion is due to 
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a failure of Sox2+ve embryonic progenitors to exit cell cycle and differentiate at earlier 
developmental stages, resulting in increased clonogenic potential by the end of gestation. In 
addition, pERK1/2 staining is strongly detected in the marginal zone, a region enriched in 
Sox2+ve stem cells at 18.5 dpc, suggesting that the MAPK pathway has a role in controlling 
stem cell specification during development and perhaps during stem cell homeostasis 
postnatally.  
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 BRAF and KRAS mutations are uncommon in pituitary adenomas (Newey at al., 2013; 
Reincke et al., 2015; Ronchi et al., 2016; Välimäki et al., 2015), but the over-activation of the 
MAPK/ERK pathway has been reported in these neoplasias. A mutation was identified in 
codon 12 of the HRAS gene (Gly to Val) in a recurrent prolactinoma that was highly invasive 
and ultimately proved to be fatal (Karga et al., 1992). Over-expression of both BRAF mRNA 
and protein has also been reported in non-functioning pituitary adenomas (Ewing et al., 
2007). Persistent MAPK/ERK pathway activation, by expressing oncogenic KRAS-G12V, 
promotes differentiation of the bi-hormonal somatolactotroph GH4 precursor cell line into a 
prolactin-secreting cell type but is not sufficient to drive tumourigenesis (Booth et al., 2014). 
In our mouse models, lactotroph differentiation is impaired rather than promoted, suggesting 
that cell context where the MAPK/ERK pathway is activated (i.e. GH4 versus embryonic 
precursors) and/or approach used (i.e. in vitro versus in vivo) may have a profound effect on 
the phenotypic outcomes. 
PCPs are benign tumours of the sellar region, mostly affecting the elderly, and can be 
associated with significant morbidity when behaving aggressively. The majority of the PCP 
tumours carry BRAF p.V600E mutations, but little is known about the consequences of the 
expression of this oncogenic protein (Brastianos et al., 2014). Of interest, preliminary data 
indicate that the use of inhibitors against BRAF-V600E and MEK may be of clinical 
relevance (Aylwin et al., 2016; Brastianos et al., 2016). Our mouse models have provided 
important insights into the molecular pathogenesis of PCP. We reveal the presence of a 
population of cycling Sox2+ cells in the basal layer surrounding the fibrovascular cores of 
PCP tumours, suggesting that these cells may be driving tumour growth. Indeed, our analysis 
shows that most of the cycling cells in the tumour are contained in the Sox2+ve cell 
compartment. It is interesting that despite the broad expression of the BRAF-V600E mutant 
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protein in the tumours, pERK1/2 staining is mostly restricted to cells surrounding the 
fibrovascular cores, a region enriched in Sox2+ve cells. This is very similar to our 
observations in the mouse models, where the activation of the pathway as evidenced by 
pERK1/2 staining mostly occurs in the Sox2+ve cells, even if all the pituitary cells express 
BRAF-V600E. In the human tumours, the squamous epithelium, which is thought to derive 
from the basal cell layer, does not express any pituitary hormone or cell-lineage commitment 
marker (PIT1, TPIT and SF1, data not shown), suggesting that as in the mouse, the activation 
of the MAPK/ERK pathway in human PCP leads to sustained proliferation and impaired 
differentiation of the Sox2+ve cells. Therefore, although there are differences between human 
PCP and the mouse models presented here, both have in common that Sox2+ve cells 
represent the major proliferative cell population and that these show impaired differentiation 
potential. The perinatal lethality in Hesx1
Cre/+
;Braf
V600E/+ 
mice precluded further analysis and 
therefore, we cannot conclude whether increased numbers of mutated Sox2+ve cells in the 
pituitary may eventually drive the formation of PCP-like tumours in these mice at an older 
age. Further refinement may be required to model PCP more accurately (e.g. using the Sox2-
CreERT2 mouse line (Andoniadou et al). Although hampered by the rarity of these tumours, 
further research aiming to test whether these cycling Sox2+ve cells may represent a tumour-
initiating cell population within human PCP is also warranted.  
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 MATERIALS AND METHODS 
 
Mice 
The Hesx1
Cre/+
, Braf
V600E/+
or Kras
G12D/+ 
mice have previously been described (Andoniadou et 
al., 2007; Mercer et al., 2005; Tuveson et al., 2004). In both the Braf
V600E/+ 
and the Kras
G12D/+ 
mouse lines the expression of the oncogenic protein is activated upon Cre-mediated 
recombination. Genotyping of mice and embryos was carried out by PCR on ear punch 
biopsies or pieces of tissue from embryos digested in DNAreleasy (Anachem) as per 
manufacturer’s instructions. The data presented in this work are representative of examples of 
at least 3 individual embryos per genotype. All the experiments performed in mice were 
carried out according to UK Home Office guidance and approved by a local ethical 
committee. 
 
Histology and in situ hybridisation on histological sections 
Haematoxylin and Eosin staining was performed as previously described (Gaston-Massuet et 
al., 2011). Histological processing of embryos and in situ hybridisation on paraffin sections 
was performed as previously described (Gaston-Massuet et al., 2008; Sajedi et al., 2008). The 
antisense riboprobes used in this study (Fgf10, Shh, Bmp4, Lhx3) have been described 
(Gaston-Massuet et al., 2008; Sajedi et al., 2008; Jayakody et al., 2012; Trowe et al., 2013). 
Full-length Braf and Kras antisense riboprobes were obtained from Source Bioscience (Clone 
ID PX00999A07 and IRAVp968D072D, respectively).  
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 EdU Labeling 
For EdU labelling of embryonic pituitaries, pregnant females at 14.5 dpc were subjected to a 
single intra-peritoneal injection of EdU at a dose of 100mg/kg and embryos dissected either 2 
hours later for short term tracing expriments or 48 hours later at 16.5 dpc for longer term 
tracing. Double immunostaining against specific markers (SOX2, PIT1, TPIT and KI67) and 
EdU was conducted using the Click-It EdU imaging kit (Invitrogen) according to 
manufacturer’s instructions. 
 
Immunohistochemistry and immunofluorescence 
Embryos were fixed in 4% PFA and processed for immunodetection as previously described 
(Jayakody et al., 2012; Andoniadou et al., 2013). Detection of hormones was carried out 
using antibodies for α-GH (NHPP AFP-5641801), α-ACTH (10C-CR1096M1), α-TSH 
(NHPP AFP-1274789), α-PRL (NHPP AFP-425-10-91), α-LH (NHPP AFP-C697071P) and 
α-FSH (AFP-7798-1289) (Developmental Studies Hybridoma Bank) at a 1:1000 dilution. 
Detection of pituitary lineage commitment was performed using antibodies for α-PIT1 (Gift 
from S. Rhodes) and α-TPIT (Gift from J. Drouin) at a 1:1000 dilution. α-SF1 (434200) 
(Thermo) was used at a dilution of 1:200. Markers of pituitary stem cells α-SOX2 (GT15098, 
Immune Systems) and α-SOX9 (AB5535, Milipore) were used at a dilution of 1:250 and 
1:500, respectively. Proliferation markers α-KI67 (ab16667, Abcam) and α-CYCLIND2 (SC-
593, Santa Cruz) were used at a dilution of 1:100 and 1:200, respectively. Detection of 
activated MAPK signaling cells was performed using α-pERK1/2 (9101, Cell Signaling) at a 
dilution of 1:250. Cytokeratins were detected using α-pan-cytokeratin recognising 
cytokeratins 5, 6, 8, 17, 19 (DMNF116; Dako M0821) at a dilution of 1:300, and an antibody 
specifically recognising cytokeratin 19 (DAKO clone RCK108; no. M088). Detection of 
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oncogenic BRAF was performed using a α-BRAF V600E antibody (Spring Bioscience; 
E19290) at a dilution of 1:50. 
 
Cell counting in vivo 
All cell counting analysis were performed in 3-5 non-consecutive histological sections 
immunostained with the specific antibodies. PIT1, SF1, TPIT, KI67, SOX2 and CyclinD2 
expressing populations were determined by taking the proportion of positive cells relative to 
total DAPI positive nuclei. Around 4000 to 7000 DAPI positive cells and 300 to 1000 
marker-positive (PIT1+, SF1+, TPIT+, KI67+, SOX2+ and CyclinD2+) cells were counted 
for each genotype. For analysis of EdU tracing experiments the proportion of either SOX2, 
PIT1 or KI67 were determined relative to the EdU positive cell population. Around 500 to 
1500 EdU positive cells and 200 to 600 marker-positive cells were counted for each 
genotype. Analysis of hormone producing cell populations (GH+, PRL+, TSH+, FSH+, LH+, 
ACTH+, αGSU+) was assessed through determining the relative proportion of hormone 
positive population to total DAPI positive nuclei in a section. These proportions were then 
applied to average cell counts of dissociated pituitaries to determine an approximation of the 
absolute numbers of these populations in the pituitary. Around 5500 to 8500 DAPI positive 
cells and 200 to 2500 marker-positive cells were counted for each genotype. 
 
Assessment of clonogenic potential 
Pituitaries from Hesx1
Cre/+
; Braf
V600E/+
, Hesx1
Cre/+
; Kras
G12D/+ 
and control littermates were 
dissected at 18.5 dpc and the posterior lobe was removed. Anterior pituitaries were 
dissociated mechanically into a single cell suspensions following incubation in an enzyme 
mix (0.5% w/v Collagenase type 2 (Lorne Laboratories Ltd), 0.1X Trypsin (Gibco) and 50 
μg/ml DNaseI (Worthington) with 2.5 μg/ml Fungizone (Gibco) in Hank’s Balanced Salt 
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Solution (HBSS (Gibco) for 4 hours at 37°C. Cells were then washed in HBSS, suspended in 
pituitary stem cell medium and seeded at densities of 2000, 4000 and 8000 cells per well of a 
6-well plate for adherent culture. Cells were cultured for 3 days at which point they were 
fixed with 4% PFA and colonies were stained for haematoxylin, as previously described 
(Gaston-Massuet et al., 2011). The proportion of colonies observed after 3 days of culture 
relative to seeded cells was used to estimate total clonogenic cells in 18.5 dpc pituitaries by 
multiplying this value by the total number of cells quantified following dissociation of the 
pituitary. 
 
RNA extraction and quantitative real-time PCR 
Pituitaries from Hesx1
Cre/+
; Braf
V600E/+ 
or Hesx1
Cre/+
; Kras
G12D/+ 
and control littermates were 
dissected at 18.5 dpc. The posterior lobe of the pituitary was discarded and the intermediate 
and anterior lobes were processed for total RNA extraction using the RNeasy Micro kit 
(Qiagen). Approximately 1 μg of total RNA was reverse transcribed to cDNA using the 
iScript Reverse Transcription Kit and random hexamers (BIORAD). Quantitative real-time 
PCR reactions were run in triplicate using the iTaq SYBR Green (BIORAD) and repeated for 
a minimum of three independent samples for each genotype. Primer sequences are available 
on request. The absolute number of mRNA copies was determined for each sample by 
comparison of obtained Cq values with that of a standard of known copy number for each 
transcript investigated. Variations in input cDNA used for each reaction were accounted for 
by normalising differences in Gapdh expression between samples and genotypes and 
applying this normalisation factor to absolute copy numbers obtained for each mRNA species 
of interest. Primer sequences are available on request. 
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 Human pituitaries and papillary craniopharyngioma samples 
Anonymised archival frozen and FFPE specimens of PCP were accessed through Brain UK. 
Human fetal pituitary tissue was accessed through the Human Developmental Biology 
Resource (HDBR). Anonymised post mortem human adult pituitary was accessed from the 
Medical Research Council Edinburgh Brain and Tissue bank and Royal Victoria Infirmary, 
Newcastle, UK (Ethical approval 
14/LO/2265). 
    
Detection of BRAF p.V600E mutations in papillary craniopharyngioma tumours 
DNA was diluted 5-fold with nuclease-free water (Ambion). Each digital PCR reaction was 
made up to 20 µL with 2 µL diluted DNA, 10 µL ddPCR™ Supermix for Probes (No dUTP; 
Bio-Rad), forward & reverse primers, dual-labelled probes for wild-type and mutant 
templates, and nuclease-free water. Sequences for the BRAF-V600E assay oligonucleotides 
are from Hindson et al. (2011) and were used at the concentrations stated. Reactions were 
partitioned into ~23,000 droplets with Droplet Generation Oil for Probes (Bio-Rad) using the 
QX200 Droplet Generator (Bio-Rad). All samples were tested in duplicate, with no-template 
controls included in all columns. Standard cycling conditions as recommended by the 
manufacturer were used with a Ta of 60°C. Results were analysed with QuantaSoft ™ 
software, v1.7. A mean of 19,080 droplets were successfully read in each well, including 
controls. Two droplets positive for wild-type template were seen in the negative controls, 
indicating a negligible degree of contamination. 
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 Statistics  
Mendelian ratios were evaluated using the chi-squared test. Clonogenic potential of control, 
Hesx1
Cre/+
;Kras
G12D/+
 and Hesx1
Cre/+
;Braf
V600E/+ 
pituitaries was evaluated using a paired t-
test. Total cell counts of control and mutant pituitaries and quantitative real-time PCR data 
were analysed by unpaired t-test. 
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  Figures 
 
 
 
Figure 1. Abnormal pituitary morphogenesis in Hesx1
Cre/+
;Kras
G12D/+
 and 
Hesx1
Cre/+
;Braf
V600E/+
 mutants. Hematoxylin and eosin staining of sagittal (A-I) or 
transverse (J-L) histological sections of the developing pituitary gland in control and mutant 
embryos; genotypes and stages are indicated. (A-C) At 10.5 dpc, Rathke’s pouch (RP) is 
morphologically comparable between genotypes. (D-I) The developing pituitary is enlarged 
and dysmorphic in the mutant compared with the control pituitary at 12.5 and 14.5 dpc 
(arrowheads). (J-L) At 18.5 dpc, the cleft is expanded and ramified in the mutant pituitaries 
(arrowheads in K,L) compared with the control (J). The posterior pituitary (PP) is comparable 
between genotypes. (M) Quantification of total numbers of cells in the control, 
Hesx1
Cre/+
;Kras
G12D/+
 and Hesx1
Cre/+
;Braf
V600E/+
 pituitaries at 18.5 dpc showing a significant 
increase in the mutants. Scale bar is 200 μm. 
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Figure 2. Braf and Kras mRNA is detected in the developing hypothalamus and 
pituitary gland. In situ hybridisation using Braf and Kras antisense riboprobes on 
histological sections of developing wild-type pituitaries. (A,D) At 10.5 dpc, weak over-all 
expression of Braf and Kras is detected in the prospective hypothalamus (Hyp) and Rathke’s 
pouch (RP). (B,E) At 12.5 dpc, strong expression is detected in the infundibulum (Inf), 
hypothalamus (Hyp), periluminal epithelium (PE) and developing anterior lobe (AL). (C,F) 
At 18.5 dpc, expression is detected in specific cells within the posterior pituitary (PP), 
intermediate lobe (IL) and the parenchyma of the anterior lobe (AL) including the marginal 
zone (MZ). Scale bar is 200μm. 
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Figure 3. Braf mRNA and BRAF-V600E protein are expressed in the developing 
pituitary in Hesx1
Cre/+
;Braf
V600E/+
 mutants. In situ hybridisation using Braf antisense 
riboprobes (A-C) and immunohistochemistry against BRAF-V600E mutant protein (D-F) on 
histological sections of Hesx1
Cre/+
;Braf
V600E/+
 embryos at indicated stages. (A-C) Braf mRNA 
expression is detected in the hypothalamic neuroepithelium (Hyp) and developing pituitary at 
all stages analysed with a similar expression pattern to the wild-type embryos (Fig. 2A-C). 
(D-F) At 10.5 dpc, only a few cells express the BRAF-V600E protein in the developing 
Rathke’s pouch (RP), but numbers increased from 12.5-18.5 dpc . Scale bar is 200μm. 
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Figure 4. Temporal and spatial regulation of pERK1/2 expression developing pituitary. 
Immunofluorescent staining against pERK1/2 on histological sections of control and mutant 
pituitaries; genotypes and stages are indicated. (A-D) Abundant pERK1/2+ve cells are 
detected in the hypothalamus (Hyp) and Rathke’s pouch (RP) at 10.5 dpc, but only very few 
cells express pERK1/2 at 12.5 and 14.5 dpc. At 18.5 dpc, most of the signal is restricted to 
the intermediate lobe (IL) and marginal zone  (MZ) of the anterior lobe. (E-L) A similar 
expression pattern is observed in both Hesx1
Cre/+
;Kras
G12D/+
 (E-H) and Hesx1
Cre/+
;Braf
V600E/+ 
(I-L) mutant pituitaries. However, the pERK1/2 signal is markedly increased at 18.5 dpc 
pituitaries (H,L) relative to the control (D). Scale bar is 200μm. 
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Figure 5. Cell-lineage commitment is disrupted in Hesx1
Cre/+
;Kras
G12D/+
 and 
Hesx1
Cre/+
;Braf
V600E/+
 mutants. Immunostaining against the commitment markers PIT1, SF1 
and TPIT on sagittal histological sections of mutant and control embryos at 14.5 dpc. (A-I) 
The expression of TPIT (A,D,G) and SF1 (B,E,H) are markedly reduced in the mutant 
pituitary, specially in the  Hesx1
Cre/+
;Braf
V600E/+
 mutant, relative to the control. In contrast, 
TPIT expression is elevated in the mutant pituitary, more apparently in the 
Hesx1
Cre/+
;Braf
V600E/+ 
genotype (C,F,I). (J) Quantification analyses demonstrate the 
significant reduction of PIT1+ve and SF1+ve cells in both mutants relative to the control 
pituitary, but the increase of TPIT+ve cells is significant only in the Braf mutants. Scale bar 
is 200μm. 
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Figure 6. Terminal differentiation of hormone-producing cells is impaired in 
Hesx1
Cre/+
;Kras
G12D/+
 and Hesx1
Cre/+
;Braf
V600E/+
 mutants. Immunostaining against pituitary 
hormones on transverse histological sections of mutant and control embryos at 18.5 dpc. (A-
R) Numbers of GH+ve (somatotrophs) (A-C), PRL+ve (lactotrophs) (D-F), TSH+ve 
(thyrotrophs) (G-I), as well as FSH+ve and LH+ve (gonadotrophs) cells (J-O) appear reduced 
in the braf and Kras mutants relative to the control pituitary. (P-R) ACTH+ve cells 
(corticotrophs and melanotrophs) look increased in the mutant pituitaries compared with the 
control. (S) Quantitative analyses demonstrate a significant reduction of all of the hormone-
producing cells in the Hesx1
Cre/+
;Braf
V600E/+
 mutant pituitary, except for ACTH+ve cells, 
which are markedly increased relative to controls. Hesx1
Cre/+
;Kras
G12D/+
 mutant pituitaries 
show a significant decrease of only PRL+ve, TSH+ve and FSH+ve cells, and ACTH+ve are 
also increased. (T) Absolute quantitative RT-PCR analysis of Gh and Acth mRNA expression 
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in mutant and control pituitaries at 18.5dpc. Significance is only reached for Gh expression, 
but there is a trend towards an increase in Acth expression.  Scale bar is 200μm. 
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Fig. 7. Increased proliferation in the Hesx1
Cre/+
;Kras
G12D/+
 and Hesx1
Cre/+
;Braf
V600E/+ 
mutant pituitaries. (A-I) Immunofluorescent staining against Ki67 on histological sections 
of mutant and control embryos; genotypes and stages are indicated. (J) Quantitative analyses 
of Ki67+ve cells out of the total DAPI+ cells demonstrate a significant increase of the 
proliferation index in the Hesx1
Cre/+
;Kras
G12D/+
 at 18.5 dpc and Hesx1
Cre/+
;Braf
V600E/+
 at 14.5 
and 18.5 dpc. Scale bar is 200μm. 
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Fig. 8. The Sox2+ve stem cell compartment is increased in Hesx1
Cre/+
;Kras
G12D/+
 and 
Hesx1
Cre/+
;Braf
V600E/+ 
mutant pituitaries. (A-I) Immunofluorescence staining revealing the 
presence of SOX2+ve cells in the developing pituitary; genotypes and stages are indicated. 
Note that the overall numbers appear elevated in the mutant pituitary relative to the controls 
at all stages analysed. (J) Quantitative analyses demonstrate that SOX2+ve cells are 
significantly increased in the mutant pituitaries compared to controls at 14.5 and 18.5 dpc. 
(K) Absolute quantitative RT-PCR analysis of Sox2 mRNA expression in mutant and control 
pituitaries at 18.5dpc. (L,M) Culture of dissociated cells reveals a significant higher 
clonogenic potential of the mutant pituitaries relative to the controls. Scale bar is 200μm. 
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Fig. 9. Abnormal balance between self-renewal and differentiation in the 
Hesx1
Cre/+
;Braf
V600E/+ 
mutant pituitaries. The nucleotide analogue EdU was administered 
once to pregnant females at 14.5 dpc and embryos analysed at 16.5 dpc. (A-C) Numbers of 
SOX2;EDU double positive cells in increased in the mutant pituitary relative to the control. 
(D-F) In contrast, the proportion of PIT1;EDU double positive cells is dramatically reduced 
in the mutant gland. (G-I) The proportion of TPIT;EDU double positive cells remained 
constant between genotypes. (J-L) The percentage of cycling cells within the initially EdU-
labelled population is significantly higher in the Hesx1
Cre/+
;Braf
V600E/+ 
mutants compared to 
controls. Scale bar is 200μm. 
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Fig. 10. Human PCP tumours contain a population of cycling SOX2+ve cells. Analysis of 
histological sections of human PCP tumours. (A, A’) Hematoxylin eosin staining showing the 
presence of fibrovascular cores (black asterisks) lined by a layer of basal cells (arrowheads) 
and large areas of suprabasal squamous epithelium (white asterisk). (B,B’) 
Immunohistochemistry revealing the expression of BRAF-V600E in a PCP tumour. Note the 
presence of staining (light brown) in the vast majority of tumour cells. Black asterisks show 
the presence of fibrovascular cores. (C,C’) Immunohistochemical detection using a pan-
cytokeratin antibody. Note that most of the tumour cells show positive staining (dark brown) 
with the exception of the basal cell layer (arrowheads) surrounding the fibrovascular cores 
(black asterisk). (D,D’) Specific staining (light brown) against cytokeratin 19 showing absent 
staining in the basal layer cells. The difference in the staining, from light to dark brown, is a 
due to technical reasons (e.g. antibody used, manual or automatized immunohistochemistry) 
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(E,E’) Immunofluorescence staining of pERK1/2 showing expression restricted to the cells 
surrounding the fibrovascular cores (white arrowheads), with some positive cells within the 
fibrovascular cores (white asterisk). (F-H) Double immunofluorescent staining shows the co-
expression of SOX2 and SOX9 in cells surrounding the fibrovascular cores, with stronger 
signal in the basal cells. (I-K) Double immunofluorescence staining reveals the co-expression 
of SOX2 and Ki67 in basal cells. (L) Quantification of SOX2:Ki67 double positive cells as a 
proportion of either the SOX2+ or Ki67+ populations in human PCP. Scale bar is 200μm, 
except in magnified inserts where it is 100μm. 
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Supplementary Table 1
Genotypes obtained from Hesx1Cre/+ χ KrasG12D/+ and Hesx1Cre/+ χ BrafV600E/+ intercrosses
Genotypes (% Expected)a
Stage
Hesx1Cre/+
KrasG12D/+
Hesx1Cre/+
Kras+/+
Hesx1+/+
KrasG12D/+
Hesx1+/+
Kras+/+
Hesx1Cre/+
BrafV600E/+
Hesx1Cre/+
Braf+/+
Hesx1+/+
BrafV600E/+
Hesx1+/+
Braf+/+
(25%) (25%) (25%) (25%) (25%) (25%) (25%) (25%)
Total Total
10.5 dpc
12.5 dpc
14.5 dpc
18.5 dpc
8 7 8 10 33
10 5 8 3 26
9 5 7 11 32
7 9 3 7 26
6 5 5 8 24
12 10 3 4 29
10 7 8 6 31
10 9 6 7 32
Embryos†
(% Observed)
34
(29%)
26
(22%)
26
(22%)
31
(26%)
117 38
(33%)
31
(27%)
22
(19%)
25
(21%)
116
Pups‡
(% Observed)
0
(0%)
10
(36%)
15
(53%)
3
(11%)
28 0
(0%)
7
(32%)
10
(45%)
5
(23%)
22
†Chi-square test showed no signifiant deviation from the expected Mendelian ratio in both Hesx1Cre/+ χ KrasG12D/+ (p=0.6598) and Hesx1Cre/+ χ 
BrafV600E/+ (p=0.1596).
‡Chi-square test showed a statistically significant deviation from the expected 25% ratio in both Hesx1Cre/+ χ KrasG12D/+ (p=0.0033) and Hesx1Cre/+ χ 
BrafV600E/+ (p=0.0219).
aDerived from expected Mendelian ratios
Development 144: doi:10.1242/dev.150490: Supplementary information
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Supplementary Table 2 
Digital PCR showing BRAF V600E mutations in human PCP samples 
Case No Diagnosis 
[DNA] 
(Copies/ 
µL) 
BRAF V600E Digital PCR 
Mean 
mutant 
copies/µL 
Mean wild-
type copies/ 
µL 
Mean % 
mutant 
87 PCP 2087 252.5 655 27.60% 
91 PCP 6653 1262.5 3302.5 27.70% 
96 PCP 360 36 240 13.00% 
97 PCP 262 11.8 72.5 14.20% 
101 PCP 1978 122.5 395 23.60% 
Development 144: doi:10.1242/dev.150490: Supplementary information
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A’ B’ C’
 
Fig. S1 Abnormal morphogenesis of the lungs in Hesx1Cre/+;BrafV600E/+ and  
Hesx1Cre/+;KrasG12D/+ mutants. (A-C) Haematoxylin and eosin staining of lung tissue 
at 18.5 dpc in Hesx1Cre/+;BrafV600E/+,  Hesx1Cre/+;KrasG12D/+ and control embryos 
showing expansion of airway structures, which are especially evident in Hesx1Cre/
+;BrafV600E/+ mutants. Scale bar is 200μm (A’-C’) Inserts show higher magnification of 
terminal airways and alveoli. Scale bar is 100μm. 
Development 144: doi:10.1242/dev.150490: Supplementary information
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Fig. S2. Normal Rathke’s pounch specification in Hesx1Cre/+;BrafV600E/+ and  
Hesx1Cre/+;KrasG12D/+ mutants.  In situ hybridisation on sagittal histological sections of 
10.5 dpc embryos; probes and genotypes are indicated. Note the comparable expression 
of Shh, Fgf10 and Bmp4 in the prospective hypothalamus and Lhx3 in Rathke’s pouch, 
between mutant and control embryos. Scale bar is 200μm.  
Development 144: doi:10.1242/dev.150490: Supplementary information
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Fig. S3. Increased cyclin D2 expression in Hesx1Cre/+;BrafV600E/+ and  
Hesx1Cre/+;KrasG12D/+ mutants. (A) immunostaining on sagittal histological sections 
revealing the elevated expression of cyclin D2 in the periluminal epithelium of Rathke’s 
pouch in the mutants relative to the control embryo. (B) Quantification of cyclin D2+ve 
cells as a proportion of the total DAPI+ve nuclei of the perilumal epithelium showing a 
higher proportion of expressing cells in the mutant embryos relative to the controls. Scale 
bar is 200μm.   
Development 144: doi:10.1242/dev.150490: Supplementary information
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Fig. S4. Reduced αGSU expression in Hesx1Cre/+;BrafV600E/+ and  Hesx1Cre/+;KrasG12D/+ 
mutants. (A) Immunostaining on transverse histological sections revealing the expression 
of αGSU in mutants and a control embryo. (B) Quantitative analysis of 
αGSU+ve cells in mutant and control pituitaries revealing a reduction in total numbers of 
αGSU+ve cells, which reaches statistical significance for the Braf-deficient mutant. Scale 
bar is 200μm. 
Development 144: doi:10.1242/dev.150490: Supplementary information
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Fig. S5. Proliferation of TPIT+ and PIT1+ progenitor populations are affected in 
Hesx1Cre/+;BrafV600E/+ mutant pituitaries at 14.5 dpc. EdU was administered once to 
pregnant females at 14.5 dpc and embryos were analysed 2 hours later. (A-C) Most of the 
labels cells are SOX2-positive with a trend towards increased numbers in the mutant 
pituitaries relative to controls (controls 74%, mutants 87%; p=0.1599). (D-I) In the 
control pituitaries, 6% of the EDU+ cells expressed PIT1 and 1.4% TPIT, whilst in the 
mutant developing glands, only 0.1% of the EDU+ cells express PIT1 and 3.7% TPIT. 
Both, the increase in TPIT and decrease in PIT1 progenitor proliferation are statistically 
significant (p=0.0246, PIT1 and p=0.0490, TPIT). Scale bar is 200μm. 
Development 144: doi:10.1242/dev.150490: Supplementary information
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Fig. S6. Expression of SOX2, SOX9 and Ki67 in human fetal and adult pituitaries. 
Immunostaining on histological sections of human pituitaries, stages and markers are 
indicated. (A-I) At embryonic stage CS20 (A-C), SOX2 and SOX9 are co-expressed in 
the vast majority of the embryonic progenitors of the developing Rathke’s pouch. In 
contrast, expression of SOX2 and SOX9 is not observed in the adult anterior pituitary (D-
F), but there are expressing cells in the posterior pituitary (G-I). (J-R) At embryonic 
stage CS20 (J-L), double immunostaining reveals the co-expression of SOX2 and the 
cycling marker Ki67 in the periluminal progenitors of Rathke’s pouch.  However, in the 
adult pituitary, Ki67+ve cells are rare and do not co-localise with SOX2+ve cells in the 
anterior (M-O) or posterior (P-R) pituitary, where they are more abundant (P). Scale bar 
is 200μm.   
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